Stockscreener 앱 받기
0.466
19.31%
-0.1115
시간 외 거래:
.48
0.014
+3.00%
Lakewood Amedex Biotherapeutics Inc 주식(LABT)의 최신 뉴스
Lakewood-Amedex Biotherapeutics Inc.Common Stock (Nasdaq:LABT) Stock Quote - FinancialContent
LABT Stock Whipsaws As Traders Focus On Cash And Volatility - Timothy Sykes
A topical candidate showed lab activity against drug-resistant bacteria from foot ulcers - Stock Titan
Is Lakewood-Amedex Biotherapeutics Inc. (LABT) Rewriting the Penny Stocks Playbook? - Kalkine Media
Lakewood-Amedex Biotherapeutics (LABT) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
How Is Lakewood-Amedex (NASDAQ:LABT) Preparing Its Nu-3 Program for Midstage Testing? - Kalkine Media
Lakewood-Amedex Biotherapeutics CEO Issues Shareholder Letter Highlighting Transformational Progress & Outlook for Nu-3 - The Columbus Dispatch
Lakewood-Amedex Biotherapeutics CEO Issues Shareholder Letter Highlighting Transformational Progress & Outlook for Nu-3 - Akron Beacon Journal
Lakewood-Amedex CEO outlines progress, Phase 2a trial ahead By Investing.com - Investing.com Canada
Before human trials, a wound gel killed drug-resistant bacteria without generating resistance - Stock Titan
Lakewood-Amedex CEO outlines progress, Phase 2a trial ahead By Investing.com - Investing.com Australia
Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3 - PR Newswire
Lakewood-Amedex CEO outlines progress, Phase 2a trial ahead - Investing.com
IPO Databook: Lakewood-Amedex Biotherapeutics (LABT US)Sep 2026 - Smartkarma
LABT Price Today: Lakewood-Amedex Biotherapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC
Lakewood-Amedex (NASDAQ: LABT) faces shareholder stock resale that brings it no cash - Stock Titan
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - openPR.com
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - Akron Beacon Journal
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - Democrat and Chronicle
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - azcentral.com and The Arizona Republic
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - Kitsap Sun
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - The Tennessean
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - The National Law Review
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - WBOC TV
Lakewood-Amedex CEO to present new antimicrobia... - Pluang
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire
Investors and potential partners will meet a biotech CEO from Lakewood-Amedex Sept. 14–16 - Stock Titan
Biotech Pre-Market Movers: BIAF, LABT, ALMS, PASW Swing Big - RTTNews
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Trending Stocks Today | SONO Group Soars 81.34% Post-Market - Moomoo
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Lakewood-Amedex Biotherapeutics Company Profile & Introduction - Moomoo
Lakewood-Amedex Biotherapeutics Becomes a B2i Digital Featured Company - markets.businessinsider.com
Lakewood-Amedex Biotherapeutics Becomes a B2i Digital Featured Company - Yahoo Finance
Lakewood-Amedex Biotherapeutics Inc. Common Stock (NASDAQ: LABT) Stock Price, News & Analysis - Kalkine
Lakewood-Amedex Biotherapeutics Inc. Common Stock (NASDAQ: LABT) Stock Price, News & Analysis - kalkine.ca
Lakewood-Amedex Biotherapeutics (LABT) investor WFI Equity discloses 8.8% ownership stake - Stock Titan
Lakewood-Amedex raises $7.5M Series C, lists on Nasdaq and clears $1.5M debt - Dealroom
Lakewood-Amedex Raises $7.5M and Lists on NASDAQ, Shedding $1.5M Debt - Minichart
LABT: Q2 net loss rose sharply on higher R&D and G&A costs; liquidity improved after Series C financing - TradingView
Lakewood-Amedex Biotherapeutics Inc. Q2 2026: Revenue $0 Net loss $(3.90M), EPS $(2.75) — 10-Q Summary - TradingView
Lakewood-Amedex (NASDAQ: LABT) raises $7.5M, expands cash yet flags going concern - Stock Titan
Upcoming and recent IPOs – IPOs calendar - Yahoo Finance Australia
Lakewood-Amedex Biotherapeutics announces annual shareholder meeting - Bitget
Lakewood-Amedex Biotherapeutics announces annual shareholder meeting - Bitget
Lakewood-Amedex (NASDAQ: LABT) seeks 100M share authorization and reverse split power - Stock Titan
Lindesfarne LLC reports 8.582% LABT stake in Lakewood-Amedex Biotherapeutics (LABT) filing - Stock Titan
Lakewood-Amedex Biotherapeutics (LABT) Earnings Date and Reports 2026 $LABT - MarketBeat
Lakewood-Amedex Biotherapeutics (LABT) asks investors to approve major share and reverse split powers - Stock Titan
Lakewood-Amedex Biotherapeutics Inc. Revenue Breakdown – NASDAQ:LABT - TradingView
4.38%
1.00%
자본화:
|
볼륨(24시간):